Last reviewed · How we verify
GL0034
At a glance
| Generic name | GL0034 |
|---|---|
| Sponsor | Sun Pharmaceutical Industries Limited |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus (PHASE2)
- Study to Evaluate if Exposure to Drug is Impacted in Participants With Renal Insufficiency (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GL0034 CI brief — competitive landscape report
- GL0034 updates RSS · CI watch RSS
- Sun Pharmaceutical Industries Limited portfolio CI